Eisai to Present New Research on Oncology Products and Pipeline at 50th Asco Annual Meeting
October 26, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Eisai to Present New Research on Oncology Products and Pipeline at 50th Asco Annual Meeting - JCN Newswire
Share:
Eisai to Present New Research on Oncology Products and Pipeline at 50th Asco Annual Meeting
 
Highlights Include New Phase Iii Clinical Data on Investigational Anticancer Agent Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer

Tokyo, May 15, 2014 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito, "Eisai") announced today that a series of abstracts highlighting new study results on Halaven (generic name: eribulin mesylate; non-taxane microtubule dynamics inhibitor, "eribulin") and lenvatinib (generic name; selective inhibitor of receptor tyrosine kinases (RTKs) with a novel binding mode) will be presented during the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, the United States, from May 30 to June 3, 2014.

The main presentations for this year's ASCO meeting include oral presentations highlighting the results of a Phase III study (the SELECT (Study of E7080 LEnvatinib in differentiated Cancer of the Thyroid) study, Study 303) with lenvatinib, an investigational agent being evaluated as a potential treatment for radioiodine-refractory differentiated thyroid cancer (RR-DTC), to be given on Monday, June 2. In addition, these findings have been chosen by ASCO to be featured in a press conference as part of the ASCO Annual Meeting press program starting at 8:00 a.m. CDT on Saturday, May 31 (Venue: E353a, McCormick Place). New data on eribulin from the pooled analysis of two Phase III trials (Study 301 and the EMBRACE trial) in patients with metastatic breast cancer is also to be presented at the meeting.

Eisai positions oncology as a key franchise area. The company will continue to create innovation in the development of new drugs based on cutting-edge cancer research, and in doing so seeks to make further contributions to address the diversified needs of, and increase the benefits provided to, patients and their families as well as healthcare providers.

About Eisai

Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.

Contact:

Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120
 


May 15, 2014
Source: Eisai

Eisai (TSE: 4523) (U.S: ESALY)

From the Japan Corporate News Network
http://www.japancorp.net
Topic: Research and development
View more news from these Sectors: Biotech, Drugs & OTC, Medical


 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)